ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Letter to the Editor
Nivolumab incuded colitis in a cancer patient: therapeutic dilemmas and patient-related factors
Abstract
Nivolumab is a current type of monoclonal IgG4 antibody used to treat many types of cancer, including stomach cancer, lymphoma, malignant melanoma and non-small cell lung cancer. Side effects associated with immune checkpoint inhibitors and tyrosine kinase inhibitors are increasingly recognized and presented as literature information. One of the most commonly affected systems is the gastrointestinal system. This case report presents a case of nivolumab-associated colitis in a patient with metastatic lung cancer, where treatment decisions were complicated by oncologic needs and patient compliance issues.

Keywords : Nivolumab, colitis, lung cancer

Download Article


1. Nassif CJ, Nassif II, Todorov M. Nivolumab-induced immune mediated colitis localized to the distal colon: seven years into therapy. Cureus. 202 4;16(10):e72373. doi:10.7759/cureus.72373
2. Kekilli M, Tanoglu A, Cakar MK, Guney G, Haznedaroglu IC. Dasatinib-induced severe hemorrhagic colitis in chronic myeloid leukemia. UHOD. 2016;1(6):67-68. doi:10.4999/uhod.740
3. Yamauchi R, Araki T, Mitsuyama K, et al. The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. BMC Gastroenterol. 2018;18(1):135. doi:10.1186/s12876-018-0864-1
4. Shibata K, Urabe F, Kurokawa G, et al. Delayed-onset immune-related colitis more than three years after nivolumab therapy for metastatic renal cell carcinoma: a case report. Int Cancer Conf J. 2025;14(3):259-263. doi:10.1007/s13691-025-00762-1
5. Muíño Domínguez D, Fernández Cadenas F, González Sánchez MH, García Calonge M, Soria Montoya A. Immuno-mediated colitis induced by nivolumab that mimics endoscopically and histologically an ulcerative colitis. Rev Esp Enferm Dig. 2024;116(12):701-702. doi:10. 17235/reed.2024.10180/2023
Article available in :
Volume 4, Issue 1, 2026
Page : 26-27
https://doi.org/10.51271/ICJIM-0071
Article Information
Received : 13 Eki 2025
Accepted : 27 Ara 2025
Published : 28 Şub 2026
Corresponding Author :

Alpaslan Tanoğlu: Department of Gastroenterology, Medical Park Göztepe Hospital Complex, Faculty of Medicine, Bahçeşehir University, İstanbul, Turkey

[email protected]
Citation : Taşkın C, Tanoğlu A. Nivolumab incuded colitis in a cancer patient: therapeutic dilemmas and patient-related factors. Intercont J Int Med. 2026;4(1):26-27.

Read: 28
Download : 53
Cited: 0
_Footer